RS49611B - Ziprasidon formulacije - Google Patents

Ziprasidon formulacije

Info

Publication number
RS49611B
RS49611B YUP-271/99A YU27199A RS49611B RS 49611 B RS49611 B RS 49611B YU 27199 A YU27199 A YU 27199A RS 49611 B RS49611 B RS 49611B
Authority
RS
Serbia
Prior art keywords
ziprasidone
formulations
crystalline
ziprasidone formulations
carrier
Prior art date
Application number
YUP-271/99A
Other languages
English (en)
Inventor
Frank Robert Busch
Angela Carol Gatlin Hausberger
Bijan Rasadi
Daniel Ray Arenson
Original Assignee
Pfizer Products Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS49611(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc., filed Critical Pfizer Products Inc.,
Publication of YU27199A publication Critical patent/YU27199A/sh
Publication of RS49611B publication Critical patent/RS49611B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyamides (AREA)
  • Detergent Compositions (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Ziprasidon formulacije, naznačene time, što sadrže kristalnu slobodnu bazu ziprasidona ili kristalne ziprasidon hidrohlorid čestice koje imaju srednju veličinu jednaku ili manju od oko 85 μm i farmaceutski prihvatljiv razblaživač ili nosilac. Prijava sadrži još 9 patentnih zahteva.
YUP-271/99A 1998-06-15 1999-06-14 Ziprasidon formulacije RS49611B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (2)

Publication Number Publication Date
YU27199A YU27199A (sh) 2002-12-10
RS49611B true RS49611B (sr) 2007-06-04

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-271/99A RS49611B (sr) 1998-06-15 1999-06-14 Ziprasidon formulacije

Country Status (45)

Country Link
US (1) US6150366A (sr)
EP (1) EP0965343B1 (sr)
JP (2) JP3441676B2 (sr)
KR (1) KR100338915B1 (sr)
CN (1) CN1307994C (sr)
AP (1) AP1216A (sr)
AR (1) AR015553A1 (sr)
AT (1) ATE240732T1 (sr)
AU (1) AU753820B2 (sr)
BG (1) BG64691B1 (sr)
BR (1) BR9902268A (sr)
CA (1) CA2274338C (sr)
CO (1) CO5070579A1 (sr)
CY (1) CY2003002I1 (sr)
CZ (1) CZ297954B6 (sr)
DE (1) DE69908021T2 (sr)
DK (1) DK0965343T3 (sr)
EA (1) EA002223B1 (sr)
ES (1) ES2197581T3 (sr)
GT (1) GT199900080A (sr)
HK (1) HK1024184A1 (sr)
HN (1) HN1999000089A (sr)
HR (1) HRP990193B1 (sr)
HU (1) HU226487B1 (sr)
ID (1) ID23546A (sr)
IL (1) IL130424A (sr)
IS (1) IS2182B (sr)
MA (1) MA26647A1 (sr)
MY (1) MY121397A (sr)
NO (1) NO316713B1 (sr)
NZ (1) NZ336271A (sr)
OA (1) OA11064A (sr)
PA (1) PA8475601A1 (sr)
PE (1) PE20000632A1 (sr)
PL (2) PL195606B1 (sr)
PT (1) PT965343E (sr)
RS (1) RS49611B (sr)
SG (1) SG77243A1 (sr)
SI (1) SI0965343T1 (sr)
SK (1) SK286245B6 (sr)
TR (1) TR199901379A2 (sr)
TW (1) TW590774B (sr)
UA (1) UA59383C2 (sr)
UY (1) UY25649A1 (sr)
ZA (1) ZA993938B (sr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
OA11946A (en) * 1999-05-27 2006-04-13 Pfizer Prod Inc Ziprasidone suspension.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
IL149352A0 (en) 1999-10-29 2002-11-10 Euro Celtique Sa Controlled release hydrocodone formulations
EP2295042A1 (en) 2000-10-30 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
JP4545584B2 (ja) 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004089948A1 (en) * 2003-04-11 2004-10-21 Hetero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
PL1617832T3 (pl) 2003-04-29 2009-01-30 Orexigen Therapeutics Inc Kompozycje wpływające na utratę wagi
KR100880279B1 (ko) * 2003-06-03 2009-01-28 테바 파마슈티컬 인더스트리즈 리미티드 결정성 지프라시돈 염산염 및 그의 제조 방법
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
US7667037B2 (en) * 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
AU2003285600A1 (en) * 2003-11-28 2005-06-24 Siddiqui Mohammed Jaweed Mukarram Process for the preparing ziprasidone monohydrochloride hydrate
CA2550485A1 (en) * 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
ES2334800T3 (es) * 2004-02-27 2010-03-16 Ranbaxy Laboratories Limited Proceso para la preparacion de ziprasidona.
JP2007536229A (ja) * 2004-05-03 2007-12-13 デューク・ユニバーシティー 体重減少に作用するための組成物
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
CN101123951A (zh) 2004-08-31 2008-02-13 辉瑞产品公司 包括低溶解性药物和聚合物的药物剂型
WO2006055603A2 (en) * 2004-11-16 2006-05-26 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
AU2006233345A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CN101198323A (zh) * 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防精神障碍的治疗组合
CN101184489B (zh) 2005-05-26 2011-01-19 大日本住友制药株式会社 药物组合物
CN101879140A (zh) * 2005-06-20 2010-11-10 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
DK1954241T3 (da) * 2005-11-28 2012-06-18 Orexigen Therapeutics Inc Zonisamid-formulering med vedvarende frigivelse
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
MX2009004874A (es) 2006-11-09 2009-06-16 Orexigen Therapeutics Inc Formulaciones farmaceuticas estratificadas que comprenden una capa intermediaria que se disuelve rapidamente.
JP2010527925A (ja) * 2007-05-18 2010-08-19 サイドース・エルエルシー ジプラシドン製剤
EP2197446A4 (en) * 2007-08-31 2012-01-25 Reddys Lab Ltd Dr PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
DK3017811T3 (en) 2010-02-25 2019-04-01 Bristol Myers Squibb Holdings Ireland APIXABAN FORMULATIONS
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
IN2015DN00042A (sr) 2012-06-06 2015-05-22 Orexigen Therapeutics Inc
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK0790236T3 (da) * 1996-02-13 2004-02-23 Pfizer Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada

Also Published As

Publication number Publication date
NO316713B1 (no) 2004-04-13
BG64691B1 (bg) 2005-12-30
HRP990193B1 (en) 2003-08-31
BR9902268A (pt) 2000-05-02
HUP9901960A3 (en) 2000-09-28
YU27199A (sh) 2002-12-10
JP2000007566A (ja) 2000-01-11
SG77243A1 (en) 2000-12-19
IS2182B (is) 2006-12-15
SK76999A3 (en) 2000-12-11
EP0965343A2 (en) 1999-12-22
PL333737A1 (en) 1999-12-20
DE69908021D1 (de) 2003-06-26
EA199900467A3 (ru) 2000-04-24
HRP990193A2 (en) 2000-02-29
TW590774B (en) 2004-06-11
EP0965343A3 (en) 2000-02-23
SI0965343T1 (en) 2003-10-31
HN1999000089A (es) 1999-11-03
MY121397A (en) 2006-01-28
US6150366A (en) 2000-11-21
JP2002003492A (ja) 2002-01-09
NO992892L (no) 1999-12-16
EA199900467A2 (ru) 1999-12-29
NZ336271A (en) 2000-10-27
TR199901379A2 (xx) 2000-01-21
HUP9901960A2 (hu) 2000-08-28
HU226487B1 (en) 2009-03-02
EA002223B1 (ru) 2002-02-28
CY2003002I1 (el) 2009-11-04
UA59383C2 (uk) 2003-09-15
PL195606B1 (pl) 2007-10-31
CZ212799A3 (cs) 2000-09-13
ES2197581T3 (es) 2004-01-01
PE20000632A1 (es) 2000-07-26
IS5079A (is) 1999-12-16
PT965343E (pt) 2003-08-29
GT199900080A (es) 2000-11-29
ID23546A (id) 2000-05-04
PL195209B1 (pl) 2007-08-31
IL130424A (en) 2003-10-31
CO5070579A1 (es) 2001-08-28
AU3398399A (en) 1999-12-23
DK0965343T3 (da) 2003-08-04
NO992892D0 (no) 1999-06-14
CN1242987A (zh) 2000-02-02
JP4187423B2 (ja) 2008-11-26
AU753820B2 (en) 2002-10-31
HK1024184A1 (en) 2000-10-05
PA8475601A1 (es) 2000-09-29
SK286245B6 (sk) 2008-06-06
MA26647A1 (fr) 2004-12-20
UY25649A1 (es) 2000-02-23
CA2274338C (en) 2003-04-15
KR100338915B1 (ko) 2002-05-30
CA2274338A1 (en) 1999-12-15
CZ297954B6 (cs) 2007-05-09
AR015553A1 (es) 2001-05-02
AP1216A (en) 2003-10-19
CN1307994C (zh) 2007-04-04
IL130424A0 (en) 2000-06-01
DE69908021T2 (de) 2003-11-27
OA11064A (en) 2002-03-13
HU9901960D0 (en) 1999-08-30
ZA993938B (en) 2000-12-14
AP9901579A0 (en) 1999-06-30
KR20000006143A (ko) 2000-01-25
ATE240732T1 (de) 2003-06-15
BG103489A (en) 2000-07-31
JP3441676B2 (ja) 2003-09-02
EP0965343B1 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
RS49611B (sr) Ziprasidon formulacije
MY116027A (en) New use
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
RS50005B (sr) Novi oblik s-omeprazola
AU2002310156A1 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
ITRM920476A1 (it) Formulazioni galeniche contenenti ciclosporina.
AP9901534A0 (en) Pharmaceutical formulations.
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
RU2001126719A (ru) Дигетерозамещенные ингибиторы металлопротеазы
RS50089B (sr) Suspenzija ziprasidona
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
RS51003B (sr) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
DK1204659T3 (da) Serotonerge benzofuraner
BG106316A (en) Ambroxol-containing lozenge
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
HRP20000400B1 (en) Transmucosal formulations of levosimendal
IT9019751A0 (it) Composizioni insetticide a base di bacillus thuringiensis
IT1318962B1 (it) Procedimento per l'invio di messaggi pubblicitari direttamente adutenti.
IT1255461B (it) Eteri di imidazoli ad attivita' a ii antagonista
EA200000112A1 (ru) Новая композиция
UY26574A1 (es) " procedimiento para la separación enzimática de racematos de derivados de aminometil-aril-ciclohexanol".
FR2662728B1 (fr) Support de faux-planchers pour salles techniques, notamment salles d'informatique.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
TR200302031T4 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin'ler ve farmasotik preparat olarak kullanımları